Literature DB >> 16575686

Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome.

L Bernd Zimmerhackl1, Nesir Besbas, Therese Jungraithmayr, Nicole van de Kar, Helge Karch, Diana Karpman, Daniel Landau, Chantal Loirat, Willem Proesmans, Friederike Prüfer, Gianfranco Rizzoni, Mark C Taylor.   

Abstract

Hemolytic uremic syndrome (HUS) includes a heterogeneous group of hemolytic disorders. Among the identified causes of HUS are infections, particularly infections with Shiga toxin-producing ESCHERICHIA COLI (STEC), complement disorders, and disorders interfering with the degradation of von Willebrand factor (VWF). Other causes for atypical HUS include the cobalamin metabolism; pregnancy/hemolysis, elevated liver enzymes, and low platelets syndrome (HELLP); drugs; and other disorders (e.g., systemic diseases appearing as HUS, such as systemic lupus erythematosus and rejection after transplantation). The group not related to STEC is often also called atypical HUS. Most of the occurrences of infectious HUS have only one episode. Recurrent episodes (recurrent HUS) have strong relationships to diseases of the complement system. In these two subgroups the prognosis is poor, with severe renal insufficiency, together with the need for renal replacement therapy. Severe arterial hypertension is common. Treatment options are limited. To better define this group of patients, the European Society for Pediatric Nephrology supported an initiative to develop a European HUS registry. In this registry, 167 patients were acquired; 73 were female (43.8%). The year of onset of the disease ranged from 1974 to 2005. The prevalence of atypical HUS/recurrent HUS can be calculated as 3.3 per million child population (< 18 years). Underlying disorders included factor H, factor I, MCP-1, pneumococci, and von Willebrand factor disturbances. In 33 patients at least one renal transplantation was performed (total, 55 kidneys); 18% were successful and 73% demonstrated recurrence or thrombosis. Treatment options were plasma substitution or plasmapheresis. Despite continued efforts, transplantation is not recommended at present for these patients. Living-related transplantation should be abandoned. New therapeutic strategies are urgently needed.

Entities:  

Mesh:

Year:  2006        PMID: 16575686     DOI: 10.1055/s-2006-939767

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  21 in total

Review 1.  [Thrombophilic states in intensive care medicine].

Authors:  L Engelmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-28       Impact factor: 0.840

2.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

3.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

4.  Different factor H-related protein patterns in siblings with typical hemolytic uremic syndrome.

Authors:  Marcus R Benz; Holger Schmid; Stefan Heinen; Bärbel Lange-Sperandio; Julia Hoefele; Thomas Sitter; Peter F Zipfel; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2011-04-21       Impact factor: 3.714

5.  cblE-Type Homocystinuria Presenting with Features of Haemolytic-Uremic Syndrome in the Newborn Period.

Authors:  Daniel Palanca; Angels Garcia-Cazorla; Jessica Ortiz; Cristina Jou; Victoria Cusí; Mariona Suñol; Teresa Toll; Belén Perez; Aida Ormazabal; Brian Fowler; Rafael Artuch
Journal:  JIMD Rep       Date:  2012-07-21

6.  Diffusion-weighted imaging of the kidneys in haemolytic uraemic syndrome.

Authors:  Jochen Herrmann; Ulrich Wenzel; Stephanie Galler; Bjoern P Schoennagel; Jasmin D Busch; Magdalini Tozakidou; Kay U Petersen; Michaela Joekel; Peter Bannas; Jin Yamamura; Michael Groth; Gerhard Adam; Christian R Habermann
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

7.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

8.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

Review 9.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

Review 10.  Clinical practice. Today's understanding of the haemolytic uraemic syndrome.

Authors:  Johanna Scheiring; Alejandra Rosales; Lothar Bernd Zimmerhackl
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.